0001493152-24-001971.txt : 20240110
0001493152-24-001971.hdr.sgml : 20240110
20240110171709
ACCESSION NUMBER: 0001493152-24-001971
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240108
FILED AS OF DATE: 20240110
DATE AS OF CHANGE: 20240110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gagnon Robert E.
CENTRAL INDEX KEY: 0001504983
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40899
FILM NUMBER: 24527279
MAIL ADDRESS:
STREET 1: C/O BIOGEN IDEC INC.
STREET 2: 133 BOSTON POST ROAD
CITY: WESTON
STATE: MA
ZIP: 02493
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bone Biologics Corp
CENTRAL INDEX KEY: 0001419554
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 421743430
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 BURLINGTON WOODS DRIVE,
STREET 2: SUITE 100,
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: (781) 552-4452
MAIL ADDRESS:
STREET 1: 2 BURLINGTON WOODS DRIVE,
STREET 2: SUITE 100,
CITY: BURLINGTON
STATE: MA
ZIP: 01803
FORMER COMPANY:
FORMER CONFORMED NAME: Bone Biologics, Corp.
DATE OF NAME CHANGE: 20140924
FORMER COMPANY:
FORMER CONFORMED NAME: AFH ACQUISITION X, INC.
DATE OF NAME CHANGE: 20071127
4
1
ownership.xml
X0508
4
2024-01-08
0
0001419554
Bone Biologics Corp
BBLG
0001504983
Gagnon Robert E.
C/O BONE BIOLOGICS CORP
BURLINGTON WOODS DR. SUITE 100
BURLINGTON
MA
01803
1
0
0
0
0
Non-Employee Stock Option
4.68
2024-01-08
4
A
0
9
0.00
A
2034-01-08
Common Stock
9
9
D
Non-Employee Stock Option
4.68
2024-01-08
4
A
0
8.006
0.00
A
2034-01-08
Common Stock
8006
8015
D
This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date.
This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, 2,003 options are immediately exercisable with the remaining 6,003 options vesting and becoming exercisable in three equal installments on 3/12/2024, 6/12/2024, and 9/12/2024.
/s/ Robert E. Gagnon
2024-01-10